Chunghwa Chemical Synthesis & Biotech Co 1762.TW · TWD
Health Care · Taiwan Stock Exchange · 🇹🇼 Taiwan
31.40
+1.45%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Chunghwa Chemical Synthesis & Biotech Co
Its shares trade on Taiwan Stock Exchange under the ticker 1762.TW. It has been listed since 10 December 2009. In the fiscal year to 31 December 2025, it reported revenue of TWD 804.9m and a net loss of TWD 243.8m. At that date it held total assets of TWD 4.32bn and shareholders' equity of TWD 3.09bn.
Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the manufacture, research and development of active pharmaceutical ingredients (API). The company is headquartered in Taipei, New Taipei. The company went IPO on 2009-12-10. The firm's biotechnology products include pravastatin, rapamycin, tacrolimus, everolimus, mycophenolate mofetil, mycophenolic acid sodium and others. Its non-biotechnology products include methocarbamol, guaifenesin, trandolapril, fluconazole, olopatadine, dexbromopheniramine maleate and glipizide, among others. Its products are applied in the manufacture of drugs for treatment of cough, diabetes, cardiovascular diseases, high blood pressure and immune system diseases. The firm distributes its products within domestic market and to overseas markets, including the rest of Asia, the Americas and Europe.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 10 Dec 2009
- Website
- ccsb.com.tw ↗
Leadership
Pay as last reported
- Ms. I-Chen Wang HsienChairman of the Board, since 2020
- Mr. Hou-Kai WangVice Chairman of the Board, since 2022
- Mr. Kuan-Chieh WangFinance Manager, Head of Finance & Accounting
- Mr. Qing-Peng WeiGeneral Manager
- Mr. Ying-Chi ChenDeputy General Manager-Business Division
- Mr. Guo-Xian ZengDeputy General Manager-Manufacturing Division
- Mr. Hou-Jie WangDirector
- Ms. Chih-Hsien ChangIndependent Director
- Mr. Arthur KuanIndependent Director
- Mr. Kuo-Chiang WangIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Chunghwa Chemical Synthesis & Biotech Co Ltd possesses several key strengths that contribute to its success in the market. These strengths include:
Weaknesses
- Despite its strengths, Chunghwa Chemical Synthesis & Biotech Co Ltd also faces certain weaknesses that pose challenges to its performance. These weaknesses include:
Opportunities
- Chunghwa Chemical Synthesis & Biotech Co Ltd can explore various opportunities to expand and enhance its market position. These opportunities include:
Threats
- To maintain its competitive position, Chunghwa Chemical Synthesis & Biotech Co Ltd must also be aware of potential threats in the market. These threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.